{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:08:36Z","timestamp":1760044116403},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2001,5]]},"DOI":"10.1016\/s0014-2999(01)01020-2","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T19:51:15Z","timestamp":1027626675000},"page":"27-32","source":"Crossref","is-referenced-by-count":19,"title":["BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of l-DOPA to the brain and reduces its O-methylation"],"prefix":"10.1016","volume":"420","author":[{"given":"Ant\u00f3nio","family":"Parada","sequence":"first","affiliation":[]},{"given":"Ana I","family":"Loureiro","sequence":"additional","affiliation":[]},{"given":"Maria Augusta","family":"Vieira-Coelho","sequence":"additional","affiliation":[]},{"given":"Dominik","family":"Hainzl","sequence":"additional","affiliation":[]},{"given":"Patr\u0131\u0301cio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0014-2999(01)01020-2_BIB1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1471-4159.1992.tb08907.x","article-title":"Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592","volume":"59","author":"Acquas","year":"1992","journal-title":"J. Neurochem."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB2","unstructured":"Benes, J., Soares-da-Silva, P., Learmonth, D.A., 2000. Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them. In: European Patent Office, vol. 2000\/25, pp. 1\u201314."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(98)00032-1","article-title":"New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease","volume":"81","author":"Bonifati","year":"1999","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB4","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/00002826-199417003-00006","article-title":"Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-l-methionine-sparing effect","volume":"17","author":"Da Prada","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.870100321","article-title":"Effects of tolcapone in Parkinson's patients taking l-dihydroxyphenylalanine\/carbidopa and selegiline","volume":"10","author":"Davis","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/0009-9236(95)90035-7","article-title":"Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans","volume":"57","author":"Dingemanse","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0006-8993(92)91003-W","article-title":"Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study","volume":"587","author":"Kaakkola","year":"1992","journal-title":"Brain Res."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1212\/WNL.44.1.77","article-title":"Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients","volume":"44","author":"Kaakkola","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/S0014-2999(01)01020-2_BIB9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00199880","article-title":"Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone","volume":"46","author":"Keranen","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB10","first-page":"333","article-title":"Catecholamine metabolism: basic aspects and clinical significance","volume":"37","author":"Kopin","year":"1985","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2165\/00023210-199401030-00002","article-title":"Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease","volume":"1","author":"M\u00e4nnist\u00f6","year":"1994","journal-title":"CNS Drugs"},{"key":"10.1016\/S0014-2999(01)01020-2_BIB12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0165-6147(89)90075-8","article-title":"New selective COMT inhibitors: useful adjuncts for Parkinson's disease?","volume":"10","author":"M\u00e4nnist\u00f6","year":"1989","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1600-0773.1990.tb00756.x","article-title":"Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease","volume":"66","author":"M\u00e4nnist\u00f6","year":"1990","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB14","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/0024-3205(88)90258-5","article-title":"Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase","volume":"43","author":"M\u00e4nnist\u00f6","year":"1988","journal-title":"Life Sci."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1476-5381.1992.tb09020.x","article-title":"Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat","volume":"105","author":"M\u00e4nnist\u00f6","year":"1992","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0014-2999(94)00682-W","article-title":"Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of l-DOPA and dopamine in rats","volume":"273","author":"Napolitano","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB17","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1212\/WNL.43.12.2685","article-title":"Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa\/carbidopa action in parkinsonian patients","volume":"43","author":"Roberts","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/S0014-2999(01)01020-2_BIB18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0006-8993(00)02158-2","article-title":"The O-methylated derivative of l-DOPA, 3-O-methyl-l-DOPA, fails to inhibit neuronal and non-neuronal aromatic l-amino acid decarboxylase","volume":"863","author":"Soares-da-Silva","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB19","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.50.6_Suppl_6.S2","article-title":"History of levodopa and dopamine agonists in Parkinson's disease treatment","volume":"50","author":"Tolosa","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/S0014-2999(01)01020-2_BIB20","first-page":"2P","article-title":"BIA 3-202, a long acting catechol-O-methyltransferase inhibitor with limited brain access","volume":"131","author":"Vieira-Coelho","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.49.3.665","article-title":"Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment","volume":"49","author":"Waters","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/S0014-2999(01)01020-2_BIB22","first-page":"375","article-title":"Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues","volume":"32","author":"Z\u00fcrcher","year":"1990","journal-title":"J. Neural Transm."},{"key":"10.1016\/S0014-2999(01)01020-2_BIB23","first-page":"641","article-title":"Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain: preclinical and clinical findings","volume":"60","author":"Z\u00fcrcher","year":"1993","journal-title":"Adv. Neurol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299901010202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299901010202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T05:29:01Z","timestamp":1555910941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299901010202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["S0014299901010202"],"URL":"https:\/\/doi.org\/10.1016\/s0014-2999(01)01020-2","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}